Literature DB >> 27085202

Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function.

Rickard P F Lindblom1, Shahin Aeinehband2, Mikael Ström2, Faiez Al Nimer2, Kerstin Sandholm3, Mohsen Khademi2, Bo Nilsson4, Fredrik Piehl2, Kristina N Ekdahl5.   

Abstract

Besides its vital role in immunity, the complement system also contributes to the shaping of the synaptic circuitry of the brain. We recently described that soluble Complement Receptor 2 (sCR2) is part of the nerve injury response in rodents. We here study CR2 in context of multiple sclerosis (MS) and explore the molecular effects of CR2 on C3 activation. Significant increases in sCR2 levels were evident in cerebrospinal fluid (CSF) from both patients with relapsing-remitting MS (n=33; 6.2ng/mL) and secondary-progressive MS (n=9; 7.0ng/mL) as compared to controls (n=18; 4.1ng/mL). Furthermore, CSF sCR2 levels correlated significantly both with CSF C3 and C1q as well as to a disease severity measure. In vitro, sCR2 inhibited the cleavage and down regulation of C3b to iC3b, suggesting that it exerts a modulatory role in complement activation downstream of C3. These results propose a novel function for CR2/sCR2 in human neuroinflammatory conditions.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complement Receptor 2; Complement system; Multiple sclerosis; Neurodegeneration; Neuroinflammation

Mesh:

Substances:

Year:  2016        PMID: 27085202     DOI: 10.1016/j.clim.2016.04.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

Review 1.  The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration.

Authors:  Ying Chen; John Man Tak Chu; Raymond Chuen Chung Chang; Gordon Tin Chun Wong
Journal:  Biomolecules       Date:  2022-02-21

Review 2.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

Review 3.  Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction.

Authors:  Ebru Karasu; Bo Nilsson; Jörg Köhl; John D Lambris; Markus Huber-Lang
Journal:  Front Immunol       Date:  2019-03-21       Impact factor: 7.561

Review 4.  The role of the complement system in Multiple Sclerosis: A review.

Authors:  Nil Saez-Calveras; Olaf Stuve
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

5.  The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcome.

Authors:  Benjamin J Cooze; Matthew Dickerson; Rukshikah Loganathan; Lewis M Watkins; Ethan Grounds; Ben R Pearson; Ryan Jack Bevan; B Paul Morgan; Roberta Magliozzi; Richard Reynolds; James W Neal; Owain W Howell
Journal:  Brain Pathol       Date:  2022-02-07       Impact factor: 7.611

Review 6.  Neuroprotective versus Neuroinflammatory Roles of Complement: From Development to Disease.

Authors:  Marlene Kanmogne; Robyn S Klein
Journal:  Trends Neurosci       Date:  2020-11-12       Impact factor: 13.837

Review 7.  Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection.

Authors:  Júlia Leão Batista Simões; Julia Beatrice de Araújo; Margarete Dulce Bagatini
Journal:  Mol Neurobiol       Date:  2021-07-11       Impact factor: 5.590

Review 8.  Microglial Pruning: Relevance for Synaptic Dysfunction in Multiple Sclerosis and Related Experimental Models.

Authors:  Maria Concetta Geloso; Nadia D'Ambrosi
Journal:  Cells       Date:  2021-03-20       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.